Diagnosis and treatment of antibody mediated rejection in lung transplantation: a retrospective case series.

Autor: Daoud AH; Division of Pulmonary and Critical Care Medicine, Henry Ford Hospital, Detroit, MI, United States., Betensley AD
Jazyk: angličtina
Zdroj: Transplant immunology [Transpl Immunol] 2013 Jan; Vol. 28 (1), pp. 1-5. Date of Electronic Publication: 2012 Dec 05.
DOI: 10.1016/j.trim.2012.11.009
Abstrakt: Introduction: Antibody mediated rejection (AMR) has been identified as an entity that may lead to graft dysfunction. Optimal means for diagnosis and treatment of AMR have not been established.
Material and Methods: We reviewed the medical records of all patients receiving lung transplantation at Henry Ford Hospital from March 2006 to December 2011. For each patient, we identified potential markers of AMR (immunopathology, histopathology, and serology). Immunopathology was defined as linear c4d immunostaining, histopathology was defined as capillaritis, and serology was defined as identification of donor specific antibody (DSA). We identified all treatment regimens, and we identified clinical and serological outcomes.
Results: Of 62 patients, 14 were identified with at least one marker of AMR. Only two patients had all three potential markers; immunopathology, histopathology, and serology. Both patients received plasmapheresis (PP) and intravenous immunoglobulin followed by clinical improvement and ultimate elimination of DSA. 4 patients had positive DSA without clinical symptoms, and did not receive treatment with PP, IVIG, or rituximab. DSA has not persisted in these patients, and they remain clinically asymptomatic at up to 803days after identification.
Discussion: Diagnosis of AMR is difficult due to poorly defined diagnostic markers and confounding factors such as infection. Outcomes are highly variable following treatment that may include therapeutic plasma exchange, intravenous immunoglobulin, and/or rituximab. It is not clear when any or all of these therapies are beneficial. In some cases, symptomatic patients with isolated positive DSA (latent humoral response) can remain asymptomatic and convert to negative DSA without antibody targeted therapy.
Conclusions: Firm conclusions are difficult due to the small number of patients and the retrospective nature of the study. Further study is warranted.
(Copyright © 2012 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: